A team of researchers at the University of Wisconsin–Madison is part of a new multi-institution effort to better understand Alzheimer’s disease in adults with Down syndrome. Adults with Down syndrome are at high risk for …
Alzheimer’s disease
Barbara Bendlin, PhD – Slide of the Week
In Alzheimer’s disease (AD), neurodegenerative processes are ongoing for years prior to the time that cortical atrophy can be reliably detected using conventional neuroimaging techniques. Recent advances in diffusion-weighted imaging have provided new techniques to study neural microstructure, which may provide additional information regarding neurodegeneration.
Mancheski Foundation funds next-gen research on Down syndrome and Alzheimer’s
A gift from the Mancheski Foundation continues to provide integral support to doctoral student Matthew Zammit as he furthers his research on the progression of Alzheimer’s disease in individuals with Down syndrome. Zammit is beginning …
Barbara B. Bendlin, PhD – Slide of the Week
Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s disease (AD), such as metabolic, cardiovascular, and cerebrovascular disease.
Bradley Christian, PhD – Slide of the Week
Trisomy 21 (Down syndrome; DS) leads to an overproduction of amyloid precursor protein and an increased risk for early Alzheimer’s disease. A study of the natural history of AD-related neuropathology is ongoing to gain an understanding of the distribution and time course of b-amyloid and tau burden in the brains of adults with DS.
Studying Alzheimer’s disease in individuals with Down syndrome
About once every year and a half, Erin Harvey takes time off of her job as a teacher’s aide and along with her mom, Nancy, makes a two and a half hour drive from her …
Barbara B. Bendlin, PhD – Slide of the Week
To test the hypothesis that cognitively unimpaired individuals with Alzheimer disease (AD) neuropathology differ from individuals with AD dementia on biomarkers of neurodegeneration, synaptic dysfunction, and glial activation.
Luigi Puglielli, MD, PhD – Slide of the Week
The aberrant accumulation of toxic protein aggregates is a key feature of many neurodegenerative diseases, including Huntington’s disease, amyotrophic lateral sclerosis and Alzheimer’s disease. As such, improving normal proteostatic mechanisms is an active target for biomedical research.
Bradley T Christian, PhD
Alzheimer’s disease is characterized by accumulation of beta amyloid (Aβ) and hyperphosphorylated tau proteins, which neuropathology suggests follow distinct spatiotemporal patterns.
Barbara Bendlin, PhD
Myelin and myelin-producing oligodendrocytes appear to be affected in Alzheimer’s disease (AD), but this is understudied in humans, particularly in the early stages of disease development.